The first patient has been enrolled in an expanded access program (EAP) trial evaluating MN-166 (ibudilast), Medicinova’s oral anti-inflammatory drug, in people with amyotrophic lateral sclerosis (AL… [+3223 chars]
1st ALS patient enrolled in MN-166 expanded access program - ALS News Today
The first ALS patient has been enrolled in an NIH-funded expanded access program trial evaluating MN-166 (ibudilast).
By:Michela Luciano, PhD
Source:ALS News Today
Published:
Related News
This Is the Vaccine Story RFK Jr. Doesn’t Want You to Hear - The Bulwark
The Trump administration says we should learn from other countries. Maybe they should have looked someplace besides Denmark.
The Bulwark•Jonathan Cohn
Close to 90% of Americans have silent heart disease, AHA says - NewsNation
The AHA acknowledged that Cardiovascular-Kidney-Metabolic syndrome (CKM) is a condition that involves a chain reaction inside the body.
Newsnationnow.com•Rob Taub
Penarth mum 'begged' for MRI which revealed cervical cancer - BBC
Jessica finally received a diagnosis after "begging" for an MRI scan revealing she needed urgent treatment.
BBC News